Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes. Issue 12 (15th October 2021)

• Record Type: Journal Article
• Authors: Khazal, Sajad; Kebriaei, Partow
• Is Part Of: Leukemia & lymphoma. Volume 62:Issue 12(2021)
• Page Start: 2831
• Page End: 2844
• Publication Date: 2021-10-15
• Subjects: Acute lymphoblastic leukemia -- hematopoietic cell transplantation -- indications -- outcome; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2021.1933475
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The treatment landscape for patients with acute lymphoblastic leukemia (ALL) is changing. Continued investigation into the biology of ALL, and broader use and more precise methods of measuring residual disease allow for improved risk stratification of patients and identification of the subset of patients at greatest risk of disease relapse and who may benefit from hematopoietic cell transplantation (HCT) in first complete remission. Further, recent advances in HCT preparative regimens, donor selection, graft manipulation, and graft-versus-host disease prophylaxis and treatment have resulted in fewer transplant-related morbidities and mortality and better survival outcomes. Finally, the development of effective immunotherapeutic salvage agents, such as the chimeric antigen receptor T-cell therapy, tisagenlecleucel, have significantly changed the treatment landscape of this disease, allowing patients with advanced disease to be considered for HCT with curative intent. In this review, we will provide an update on the indications and outcome of pediatric and adult ALL.